HROW EBITDA
$11.19MTTM · USD
Period ending:
HROW FY EBITDAUSD
$42.13M-$14.21M
2005-12-312025-12-31
Source: Financial Modeling Prep (FMP). Annual fiscal periods; reported in USD. Dates are period ends; a fiscal year may differ from a calendar year.
HROW ebitda history
Earnings before interest, taxes, depreciation, and amortization. The available annual fiscal periods series contains 21 observations from Dec 31, 2005 to Dec 31, 2025.
| Period ending | EBITDA (USD) |
|---|---|
| 42,133,000 | |
| 23,612,000 | |
| 13,151,000 | |
| -3,102,000 | |
| 5,759,000 | |
| 3,491,000 | |
| 1,908,000 | |
| -3,374,000 | |
| -10,398,000 | |
| -14,173,000 | |
| -14,212,000 | |
| -10,062,000 | |
| -7,637,465 | |
| -5,356,000 | |
| -879,000 | |
| -2,475,000 | |
| -4,553,000 | |
| -4,121,000 | |
| -2,519,748 | |
| -46,206 | |
| -536,000 |
Compare ebitda
Other companies in Health Care. Each page shows its own reporting periods and currency.
- Guardant Health Inc (GH) ebitda
- Bridgebio Pharma Inc (BBIO) ebitda
- Brightspring Health Services Inc (BTSG) ebitda
- Madrigal Pharmaceuticals Inc (MDGL) ebitda
- Ensign Group Inc (ENSG) ebitda
- Glaukos Corp (GKOS) ebitda
- Vaxcyte Inc (PCVX) ebitda
- Krystal Biotech Inc (KRYS) ebitda
All HROW financial metrics · HROW stock overview · How to interpret financial metrics
